Business Wire

TreviPay Introduces All-in-One Payments Solution for Accepting Net Terms and Card Payments at Checkout

5.12.2023 15:00:00 EET | Business Wire | Press release

Share

TreviPay, the global B2B payments and invoicing network, today released a series of technology features designed to help merchants build experiential loyalty with enterprise buyers, including TreviPay’s new all-in-one payments solution. By providing payment choice, convenience and customization, merchants across different industries, including retail, hospitality and manufacturing, can leverage TreviPay’s technology to reduce friction and build loyalty at all stages of the purchasing process.

Recent TreviPay research unveiled the importance of payment choice for optimizing first-time and returning buyer experiences with 86% of global business buyers reporting the ability to pay using their preferred payment method is important. With TreviPay’s all-in-one payments, B2B merchants and marketplaces can now serve the entire spectrum of business buyers with TreviPay as their single payments vendor. Through integration, merchants can customize acceptance of card types, allowing business buyers to either pay upfront with card, ACH or mobile wallet, or pay later through net terms (the ability to pay in 30-, 60-, or 90-days) and invoicing to improve cash flow and reduce bad debt.

“As enterprises continue to evaluate their digital transformation efforts, there is still an opportunity to innovate the online B2B payments experience to eliminate checkout friction and increase conversions,” said Dan Zimmerman, Chief Technology Officer of TreviPay. “Through one comprehensive checkout solution, merchants can rely on a single payments vendor to accept multiple payments modalities and consolidate reporting across payment types.”

A notable use case is found in the B2B retail industry where credit cards are often the only payment option offered online. As trade credit or net terms are preferred by 85% of global business buyers, typically for higher spend or more frequent purchases, retailers can now accommodate both options more seamlessly through TreviPay’s all-in-one payments solution. Credit and debit card payments are supported for customers in the U.S., Canada, Mexico, U.K., Europe and Australia, in 16 payout currencies and 25+ locales. TreviPay APIs also provide integrated reporting to systematically deliver detailed reimbursement documentation daily, as well as consolidated reporting for card and net terms payments and deposits — at the marketplace and individual seller levels.

Additional technology capabilities now offered by TreviPay to bolster buyer loyalty include:

  • Decentralized Billing: For sellers to create billing groups and sub-tiered accounts (parent/child hierarchy) with separate legal entities, to configure custom payment and billing options, as well as apply individual credit limits.
  • Contract Price Verification: For sellers to define customer pricing tiers with specific SKU-level pricing details, for TreviPay to conveniently cross-reference against contracted pricing with limited disruption.
  • Customized Customer Support: For sellers to define and rank buyers to customize support with white-glove services, such as offering extended net terms or assigning a dedicated support agent.
  • Customer Portal Redesign: To improve navigation, usability and customer experience for buyers, with easy-to-export data capabilities.

To learn more about TreviPay’s solutions for growing B2B experiential loyalty, visit www.trevipay.com.

About TreviPay

At TreviPay, we believe loyalty begins at the payment. By understanding the diverse and unique requirements of B2B sellers, TreviPay’s global B2B payments and invoicing network enables enterprises to provide payments choice and convenience, open new markets and automate accounts receivables. With more than four decades of experience, TreviPay serves leaders looking to build loyalty while driving efficiency and embracing new digital channels, especially in industries with large distribution networks such as manufacturing, retail and transportation. For more information, visit trevipay.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alissa Clayton
The Fletcher Group
647.390.9085
alissa@fletchergroupllc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye